ClinicalTrials.gg
CompletedNCT01551888Updated Feb 14, 2017Results posted

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Aclidinium/formoterol 400/12μg and Formoterol in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-02-14.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
173rd of 194
24 · median 137
Started
2012
with 17 others
Phase 2
54 of 284
1 open now
Registered
118th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 173rd largest by enrollment of the 194 interventional ones that give a count, is one of 18 that started in 2012, is one of 54 in phase 2, and was the 118th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall Inhaler and formoterol 12 μg via the Foradil® Aerolizer®, both administered twice daily for five days to patients with moderate to severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Chronic Bronchitis
  • Emphysema
  • Airflow Obstruction, Chronic
  • Chronic Airflow Obstruction
  • Chronic Obstructive Airway Disease
  • Chronic Obstructive Lung Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current or former cigarette smokers with a cigarette smoking history of at least 10 pack-years
  • A diagnosis of stable moderate to severe and stable airway obstruction as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable airway obstruction.

Exclusion criteria

Exclusion Criteria:

  • Patients who have been hospitalized for an acute exacerbation within three months prior to Screening
  • Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Screening
  • Patients with any respiratory conditions other than COPD
  • Clinical history that suggests that the patient has asthma as opposed to COPD
  • Chronic use of oxygen therapy ≥ 15 hours/day
  • Patients with clinically significant cardiovascular conditions
  • Patients with a history of reaction to inhaled anticholinergics, beta-2 agonists, sympathomimetic amines, or inhaled medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Aclidinium/formoterol 400/12μg FDC

    Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler

    Drug: Aclidinium/formoterol 400/12μg

  • Active comparator
    Formoterol

    Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®

    Drug: Formoterol

Interventions

  • DrugAclidinium/formoterol 400/12μg

    Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler

  • Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®

    Also known as: Foradil® Aerolizer®

06

What researchers measure

Primary outcomes

  1. Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State

    The standard deviation of the measure is expressed as the coefficient of variation (%)

    Time frame: Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)

  2. Maximum Formoterol Plasma Drug Concentration (Cmax) at Steady State

    The standard deviation of the measure is expressed as the coefficient of variation (%)

    Time frame: Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)

  3. Maximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose

    The standard deviation of the measure is expressed as the coefficient of variation (%)

    Time frame: Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose

Secondary outcomes

  1. Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval Following a Single Dose

    The standard deviation of the measure is expressed as the coefficient of variation (%)

    Time frame: Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose

07

Results

Posted Nov 23, 2016

Participant flow

The study was conducted in a single center in the United States First patient visit was in January 2012 and last patient visit was in March 2012

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2
Started1212
Completed1212
Not completed00
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryArea Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State

The standard deviation of the measure is expressed as the coefficient of variation (%)

Time frame:
Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)
Reported as:
Mean · pg*hr/mL
Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State
pg*hr/mLFormoterol 12 μgAclidinium/Formoterol 400/12 μg FDC
Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State87.14 ± 27.885.15 ± 28.3
PrimaryMaximum Formoterol Plasma Drug Concentration (Cmax) at Steady State

The standard deviation of the measure is expressed as the coefficient of variation (%)

Time frame:
Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose)
Reported as:
Mean · pg/mL
Maximum Formoterol Plasma Drug Concentration (Cmax) at Steady State
pg/mLFormoterol 12 μgAclidinium/Formoterol 400/12 μg FDC
Maximum Formoterol Plasma Drug Concentration (Cmax) at Steady State14.90 ± 27.916.72 ± 31.6
SecondaryArea Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval Following a Single Dose

The standard deviation of the measure is expressed as the coefficient of variation (%)

Time frame:
Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose
Reported as:
Mean · pg*hr/mL
Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval Following a Single Dose
pg*hr/mLFormoterol 12 μgAclidinium/Formoterol 400/12 μg FDC
Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval Following a Single Dose41.63 ± 32.242.27 ± 31.3
PrimaryMaximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose

The standard deviation of the measure is expressed as the coefficient of variation (%)

Time frame:
Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose
Reported as:
Mean · pg/mL
Maximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose
pg/mLFormoterol 12 μgAclidinium/Formoterol 400/12 μg FDC
Maximum Formoterol Plasma Drug Concentration (Cmax) Following a Single Dose8.23 ± 39.99.55 ± 39.0

Adverse events

Collected over Up to study Day 17. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aclidinium/Formoterol 400/12 μg—0/24 (0%)0/24 (0%)
Formoterol 12 μg—2/24 (8.3%)0/24 (0%)
Most frequent serious events
Most frequent serious events
EventAclidinium/Formoterol 400/12 μgFormoterol 12 μg
Aortic valve incompetenceCardiac disorders0/241/24
Lacunar infarctionNervous system disorders0/241/24
Aortic aneurysmVascular disorders0/241/24

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall Study Population
Mean60.9 ± 7.5
Gender
Gender(Participants)Overall Study Population
Female10
Male14
08

Study locations

1 site
  • Forest Investigative Site 001
    Spartanburg, South Carolina 29303, United States
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 4 years 8 months after primary completion. A results delay was requested in Aug 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 13, 2012
Start
Jan 2012
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results delay requested
Aug 22, 2012
Results first posted
Nov 23, 2016
Last update
Feb 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01551888
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Jan 2012
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Nov 23, 2016
Last update
Feb 14, 2017

Study contacts

Esther Garcia, MD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion